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What is already known on this topic?
 ► It is not currently possible to identify gold 
standard treatments for children with 
gastroschisis, partly because of outcome 
reporting heterogeneity.
 ► Many gastroschisis studies investigate 
outcomes that are not relevant to patients or 
clinical practice.
 ► The use of core outcome sets in research 
reduces outcome reporting heterogeneity and 
helps improve the clinical relevance of research.
What this study adds?
 ► This study has developed a gastroschisis core 
outcome set consisting of eight outcomes that 
are important to parents, people born with 
gastroschisis and clinicians.
 ► The eight outcomes are death, sepsis, growth, 
number of operations, time on parenteral 
nutrition, liver disease, number of severe 
gastrointestinal complications and quality of 
life.
 ► The core outcome set can be used in future 
observational and interventional studies and 
will reduce outcome reporting heterogeneity 
and increase clinical relevance of studies.
AbsTrACT
Objective Outcome reporting heterogeneity impedes 
identification of gold standard treatments for children 
born with gastroschisis. Use of core outcome sets (COSs) 
in research reduces outcome reporting heterogeneity and 
ensures that studies are relevant to patients. The aim of 
this study was to develop a gastroschisis COS.
Design and setting Systematic reviews and 
stakeholder nomination were used to identify candidate 
outcomes that were subsequently prioritised by key 
stakeholders in a three-phase online Delphi process and 
face-to-face consensus meeting using a 9-point Likert 
scale. In phases two and three of the Delphi process, 
participants were shown graphical and numerical 
representations of their own, and all panels scores for 
each outcome respectively and asked to review their 
previous score in light of this information. Outcomes 
were carried forward to the consensus meeting if 
prioritised by two or three stakeholder panels in the 
third phase of the Delphi process. The COS was formed 
from outcomes where ≥70% of consensus meeting 
participants scored the outcome 7–9 and <15% of 
participants scored it 1–3.
results 71 participants (84%) completed all phases 
of the Delphi process, during which 87 outcomes were 
assessed. Eight outcomes, mortality, sepsis, growth, number 
of operations, severe gastrointestinal complication, time on 
parenteral nutrition, liver disease and quality of life for the 
child, met criteria for inclusion in the COS.
Conclusions Eight outcomes have been included in the 
gastroschisis COS as a result of their importance to key 
stakeholders. Implementing use of the COS will increase the 
potential for identification of gold standard treatments for 
the management of children born with gastroschisis.
InTrODuCTIOn
Gastroschisis is increasing in incidence and is esti-
mated to affect between 3.6 and 4.4 per 10 000 live 
births in the UK.1 2 As with many neonatal surgical 
conditions, there are a number of treatment options 
in everyday use, and for gastroschisis, the two most 
common are operative primary fascial closure and 
silo placement, followed by staged reduction and 
delayed closure. Strategies for immediate post-
operative management, introduction of enteral 
feeding and parenteral nutritional support also vary 
widely. There is therefore robust debate among the 
paediatric surgical and neonatal communities as to 
which intervention or combination of interventions 
produces the best outcomes, and due to limitations 
with the primary evidence base, it is not currently 
possible for systematic reviews to reliably inform 
this debate. Limitations of the primary evidence 
base include the small sample size and retrospective 
nature of many of the studies and the existence 
of significant outcome reporting heterogeneity.3 4 
Outcome reporting heterogeneity suggests there is 
a lack of consensus among researchers as to which 
outcomes should be used to define success of treat-
ment in a particular condition and indicates that 
studies are at risk of lacking relevance to patients, 
of being affected by reporting bias and being diffi-
cult to meta-analyse.
A core outcome set (COS) is a group of outcomes 
that have been identified by key stakeholders as 
being the most important in determining success 
of treatment of a particular condition. Once a COS 
has been developed for a particular condition, all 
future studies conducted within the scope of the 
COS should investigate and report as a minimum 
all outcomes included within the COS.5 Additional 
outcomes can also be investigated and reported if 
appropriate for the study, but the reporting at a 
minimum of all core outcomes ensures that a study 
will be relevant to patients and clinical practice, at 
a low risk of reporting bias and meta-analysable 
with other studies investigating the same clinical 
question.5 The aim of this study was therefore to 
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Figure 1 Summary of the gastroschisis core outcome set (COS) development process.
develop a COS that could be used in studies comparing the 
overall success of postnatal treatments for children born with 
gastroschisis.
MeThODs
Protocol registration
The protocol was prospectively registered in October 2014 on 
the Core Outcome Measures in Effectiveness Trials (COMET) 
initiative website (http://www. comet- initiative. org/ studies/ 
searchresults? guid= d1e190c8- a2eb- 4d49- a341- 7d3ec79be12c) 
and published in a peer-reviewed journal.6
scope
The COS is intended for use in studies comparing postnatal inter-
ventions for the treatment of children born with gastroschisis in 
high-income countries. It is likely that outcomes of importance 
in low-income and middle-income countries will be different to 
those that are important in high-income settings, and therefore, the 
relevance of the COS to studies conducted in these settings should 
be considered prior to it being used. The COS is also not intended 
to be applicable to studies investigating antenatal interventions or 
factors related to the mode or timing of delivery of babies with a 
prenatal diagnosis of gastroschisis.
Process
Three panels of stakeholders completed a three-phase online 
Delphi process in order to prioritise outcomes identified 
from a systematic review and stakeholder nomination. Priori-
tised outcomes were discussed and rescored at a face-to-face 
consensus meeting, and those that met a prespecified threshold 
were included in the final COS. A separate face-to-face meeting 
was held to identify measurement definitions for each outcome 
included in the COS (figure 1).
Participants
So as to represent the full spectrum of clinical and personal 
experience of gastroschisis, participants were recruited across 
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Table 1 Stakeholder recruitment strategies
stakeholder group Panel recruitment methods
People born with 
gastroschisis
Personal experience 
panel
Mailing lists, websites and Facebook groups of UK and international gastroschisis support groups.
Parents of children born 
with gastroschisis
Mailing lists and meetings for a Parental Advisory Group established by the National Perinatal Epidemiology Unit.
Paediatric surgeons Neonatal panel Direct approaches to experts known to members of the SMG and those identified on a search of the British Association of 
Paediatric Surgeons (BAPS) register as having a special interest in management of children with gastroschisis.
BAPS mailing lists, newsletters and website.
Direct approach to clinical leads at each paediatric surgical centre in the UK for the BAPS-CASS gastroschisis study.
Neonatologists Neonatal panel Direct approach to experts known to members of the SMG.
Mailing lists, bulletin and website of the British Association of Perinatal Medicine.
Fetal medicine specialists Neonatal panel Direct approach to experts known to members of the SMG.
Mailing list of the fetal medicine clinical study group of the British Maternal and Fetal Medicine Society.
Specialist nurses Neonatal panel Direct approaches to experts known to members of the SMG.
Mailing list of the Neonatal Nurses Association and the National Neonatal Surgical Benchmarking Group.
Paediatricians Non-neonatal panel Direct approach to experts known to members of the SMG.
Mailing list of the British Society of Paediatric Gastroenterology Hepatology and Nutrition.
Researchers Non-neonatal panel Direct approaches to experts known to members of the SMG and prominent gastroschisis researchers identified through 
searches of the literature.
Specialist paediatric surgical 
nurses
Neonatal panel Direct approach to experts known to members of the SMG.
Dietitians Non-neonatal panel Direct approach to experts known to members of the SMG.
Mailing list of the British Society of Paediatric Gastroenterology Hepatology and Nutrition.
BAPS-CASS, British Association of Paediatric Surgeons Congenital Anomalies Surveillance System; SMG, Study Management Group.
a range of clinical specialties involved in the treatment of chil-
dren born with gastroschisis and also from families where one 
or more people had been born with gastroschisis. Experts were 
recruited according to the strategies described in table 1 with 
those selected to participate asked to nominate additional poten-
tially eligible stakeholders. Clinical stakeholders were recruited 
only from the UK in order to ensure funding could be used to 
maximise the number of participants attending the consensus 
meeting while also maintaining the meeting attendee’s repre-
sentativeness of the wider study participants. Prior to inclusion 
in the study, experts were asked to register their interest via a 
customised website, where details were collected documenting 
their experience of gastroschisis. Registrations were reviewed by 
the Study Management Group (SMG) to ensure that participants 
had sufficient expertise in gastroschisis management or lived 
experience of gastroschisis to participate in the study.
Data presentation throughout the Delphi process was simplified 
by combining stakeholder groups into a neonatal panel, a non-neo-
natal panel and a personal experience panel as described in table 1, 
within which, opinions were anticipated to be broadly similar.
Information sources
Two systematic reviews, each with a prospectively registered 
protocol, were conducted by separate groups who had each set 
out to develop a COS for use in determining the overall success 
of treatment for a child born with gastroschisis. The first of these 
reviews was a broad, scoping review, including all comparative 
study designs,7 while the second focused solely on randomised 
controlled trials and systematic reviews.8 Outcomes identified from 
the systematic reviews were assessed by the SMG and mapped to 
unique terms. Outcomes assessing the success of antenatal interven-
tions were dropped as they were outside of the scope of the COS.
In phase one of the Delphi process, stakeholders were asked 
to propose additional outcomes that they felt were important 
but had not been identified by the systematic reviews. These 
outcomes were reviewed by the SMG, and if within the scope 
of the COS, were taken forward for assessment in phase two of 
the Delphi process. See online supplementary material 1 for list 
of all outcomes considered at any stage.
Dropping and modification of outcomes
No outcomes were dropped between phase one and phase two 
of the Delphi process. Between phase two and phase three, 
outcomes were dropped if ≥50% of participants in all panels 
scored them 1–3 and <50% of participants in any panel scored 
them 7–9. Outcomes were automatically discussed at the 
consensus meeting if in phase three of the Delphi process two 
or more panels deemed them to meet the threshold for inclu-
sion in the COS. As per guidance from the COMET initiative, 
the threshold for inclusion in the COS was defined as ≥70% 
of participants scoring an outcome of 7–9, and <15% scoring 
1–3.9 Other outcomes were only discussed and rescored at the 
consensus meeting if there was unanimous agreement among the 
meeting attendees that they warranted further discussion.
Comments were sought from participants in relation to 
clarity of outcome descriptions throughout each phase of the 
Delphi process. All comments were reviewed by the SMG, and 
if necessary, outcome descriptions/terminology were modified to 
improve their clarity and understanding.
Consensus definition
Outcomes were deemed to have met consensus for inclusion 
in the COS if ≥70% of participants at the consensus meeting 
scored them 7–9 and <15% scored them 1–3.
Assessment of attrition bias
Median phase one scores for the outcomes included in the COS 
(or their nearest approximation where the outcome was added 
after phase one) were compared between participants within 
each panel who completed all three phases of the Delphi process 
and those who only completed phase one. Wilcoxon rank-sum 
test was used to compare scores, and in order to reduce the risk 
copyright.
 o
n
 4 February 2019 by guest. Protected by
http://fn.bmj.com/
Arch D
is Child Fetal Neonatal Ed: first published as 10.1136/archdischild-2017-314560 on 14 M
arch 2018. Downloaded from
 
F79Allin BSR, et al. Arch Dis Child Fetal Neonatal Ed 2019;104:F76–F82. doi:10.1136/archdischild-2017-314560
Original article
Table 3 Outcomes discussed at the consensus meeting, categorised into OMERACT filter 2.0 core areas
Mortality 
outcomes Life impact outcomes
Pathophysiological  
manifestation outcomes resource utilisation outcomes Adverse event outcomes
Mortality Home parenteral nutrition Quality of life for the child Short bowel syndrome Abdominal compartment syndrome†
Need for total parenteral nutrition 
postdischarge
Bowel lengthening procedure required Cholestasis Bowel ischaemia
Reoperation Time on total parenteral nutrition Unspecified measures of growth* Bowel obstruction†
Societal costs, including financial 
costs for the family
Time on parenteral nutrition Bowel resection†
Rehospitalisation Liver transplant Intestinal perforation†
Length of stay* Small bowel transplantation Necrotising enterocolitis†
Need for a permanent stoma Infection with systemic sequelae
Chronic GI symptoms Anastomotic stricture
Gastrointestinal dysfunction Gastrointestinal complication†
Neurodevelopmental outcomes Intestinal failure associated liver disease
*Outcomes not meeting criteria for automatic discussion at the consensus meeting and only promoted after unanimous agreement by the meeting attendees.
†Outcomes combined to the composite outcome severe gastrointestinal complication.
GI, gastrointestinal.
Table 2 Study participants
number of participants
registering for 
round one
Completing round one 
(% of those eligible)
Completing round two 
(% of those eligible)
Completing round three 
(% of those eligible)
Consensus 
meeting
Measurement 
meeting
Neonatal panel 58 52 (90) 47 (90) 43 (91) 15 10
Non-neonatal panel 8 8 (100) 7 (88) 6 (86) 4 3
Personal experience panel 98 42 (43) 31 (74) 22 (71) 5 1
Total 164 102 (62) 85 (83) 71 (84) 24 14
of a type I error, the Bonferroni correction was used to set the 
level of significance at a P value of <0.002.
resuLTs
Protocol modifications
It was initially proposed that people born with gastroschisis 
and parents of children born with gastroschisis should only 
be recruited from the UK. However, despite extensive work 
with gastroschisis charities, it proved difficult to recruit to 
these stakeholder groups when participation was limited to 
the UK. It was therefore decided by the SMG that it was 
more important to ensure a strong voice of personal expe-
rience throughout the study than it was to ensure that it 
was feasible for all participants to have the opportunity to 
attend the consensus meeting, and recruitment was there-
fore expanded to include people with personal experience 
of gastroschisis who were treated in other high-income 
countries. Participants in other stakeholder groups were still 
restricted to those based in the UK.
It was initially proposed that no outcomes would be dropped 
between phases of the Delphi process. However, after publi-
cation of the protocol, but prior to phase one of the Delphi 
process, it was decided by the SMG that in order to allow partic-
ipants to focus on outcomes likely to be of greater importance, 
they should instead be retained as described in the dropping and 
modification of outcomes section.
Participants
One hundred and sixty-four people registered to participate in 
the Delphi process, 102 (62%) of whom completed phase one. 
Eighty-five (83%) of 102 eligible participants then completed 
phase two, and 71 (84%) of 85 eligible participants completed 
phase three (table 2).
Of the 71 participants that completed all three phases of the 
Delphi process, 19 (27%) were paediatric surgeons, 13 (18%) 
were neonatologists, 11 (16%) were specialist nurses, 2 (3%) 
were paediatric gastroenterologists, 2 (3%) were paediatric dieti-
cians and 22 (31%) were parents of children born with gastro-
schisis. Fourteen (64%) of the parents who completed all three 
phases of the Delphi process had children born with gastroschisis 
who were less than 5 years of age at the time of the study, four 
(18%) had children between 5 and 10 years of age, two (1%) had 
children over 10 years of age and two (1%) preferred not to say 
how old their child was.
Outcomes
Following review by the SMG and removal of outcomes outside 
the scope of the COS, 75 outcomes were carried forward from 
the systematic reviews to phase one of the Delphi process. Twelve 
additional outcomes were proposed during phase one, leading to 
assessment of 87 outcomes in phase two, 86 (99%) of which were 
carried forward to phase three (online supplementary material 
1). Following scoring in phase three, 28 outcomes (33%) met 
the criteria for automatic discussion at the consensus meeting, 
with two additional outcomes discussed following unanimous 
agreement by the meeting attendees that they warranted further 
review (table 3). Eight outcomes (box 1 and table 4) met the 
criteria for inclusion in the COS, with the additional outcome 
societal cost (including financial cost to the family) noted as 
important by the meeting attendees but not included within the 
COS due to the lack of ability to accurately measure such an 
outcome at present.
copyright.
 o
n
 4 February 2019 by guest. Protected by
http://fn.bmj.com/
Arch D
is Child Fetal Neonatal Ed: first published as 10.1136/archdischild-2017-314560 on 14 M
arch 2018. Downloaded from
 
F80 Allin BSR, et al. Arch Dis Child Fetal Neonatal Ed 2019;104:F76–F82. doi:10.1136/archdischild-2017-314560
Original article
box 1 Continued
fissure), and at least one of pneumatosis intestinalis, hepatobiliary gas, 
pneumoperitoneum’.
CSF, cerebrospinal fluid; PedsQL, pediatric quality of life inventory.
box 1 The gastroschisis core outcome set
Death
 ► Number (%) of infants who have died.
sepsis
 ► Median (IQR and range) number of times treatment was given for 
proven or presumed sepsis.
 ► Number of episodes where sepsis was proven by a positive blood 
or CSF culture should be reported separately from the number of 
episodes where treatment was given for sepsis, but the blood or CSF 
culture was negative.
Growth
 ► Median (IQR and range) z-score for weight, length and head 
circumference in studies reporting outcomes at or prior to 1 year of 
age.
 ► Median (IQR and range) z-score for weight and height in studies 
reporting outcomes after 1 year of age.
number of operations
 ► Median (IQR and range) number of operations per infant.
 ► The type of operations undertaken should be categorised according 
to whether they were performed under general or local anaesthetic 
and whether they were an abdominal operation, central venous 
catheter insertion or ‘other’ operation. ‘Other’ operations should 
only be reported when performed under general, not local, 
anaesthetic.
 ► Each episode of silo placement, replacement and reapplication 
should be reported as a separate abdominal operation, with 
abdominal closure reported separately to silo placement.
severe gastrointestinal complication
 ► Median (IQR and range) number of severe gastrointestinal 
complications per infant.
 ► Severe gastrointestinal complication only includes:
 – intestinal perforation
 – any intestinal resection, regardless of amount of bowel removed 
or the indication for the resection
 – mechanical intestinal obstruction resulting in a repeat 
laparotomy
 – abdominal compartment syndrome*
 – enterocolitis.†
Time on parenteral nutrition
 ► Median (IQR and range) number of days any parenteral nutrition 
was received per infant in studies reporting outcomes at or prior to 
1 year of age.
 ► Number (%) of infants receiving any parenteral nutrition in studies 
reporting outcomes after 1 year of age.
Liver disease
 ► Number (%) of infants with persistent conjugated 
hyperbilirubinaemia (>50 μmol/L) for ≥2 weeks with no known 
other underlying liver disease.
Quality of life for the child
 ► Median (IQR and range) PedsQL score in each study group.
 ► If appropriate, the median (IQR and range) score from the PedsQL 
gastrointestinal symptoms and family impact modules in each study 
group should also be reported.
*Defined as ‘suspected raised intra-abdominal pressure with at least two 
of oliguria or anuria, respiratory de-compensation, hypotension/shock, or 
metabolic acidosis, that leads to intervention’.
†Defined as ‘suspected enterocolitis with at least one of bilious aspirates 
or emesis, abdominal distension or occult or gross blood in stool (no 
Continued
Table 4 Outcomes meeting consensus for inclusion in the 
NETS1G core outcome set
Core outcome score 7–9 (%) reporting time-points
Death 100 Cohort or intervention study time-points
Sepsis 100 Cohort or intervention study time-points
Growth 100 Cohort or intervention study time-points
Number of operations 100 Cohort or intervention study time-points
Severe gastrointestinal 
complication
96 Cohort or intervention study time-points
Time on parenteral 
nutrition
87 Cohort study time-points only
Liver disease 74 Cohort or intervention study time-points
Quality of life  
for the child
73 Cohort or intervention study time-points
NETS, Next Stage in Evidence-based paediatric surgical Treatment Strategies 1 - 
Gastroschisis.
Definition and measurement of outcomes
A literature review informed by a previously published system-
atic review7 identified existing definitions, measurement tools 
and common measurement time-points for outcomes included 
in the COS. The 14 attendees at the measurement meeting were 
asked to review summaries of this literature in advance of the 
meeting in order to guide discussion among the group. Following 
discussion, unanimous agreement was reached on definitions 
and methods of measurement for each core outcome (box 1). 
Appropriate time-points for reporting these core outcomes 
were also discussed, and it was unanimously agreed that these 
should be kept as close as possible to standard time-points for 
reporting surgical and paediatric outcomes (table 5). In order 
to make future meta-analysis more meaningful, studies using 
the developed COS should report outcomes at at least one of 
these time points. Further rationale for selection of these time-
points, and for using different time-points for intervention and 
cohort studies is described in detail in a previously published 
Hirschsprung’s disease COS development study.10
Attrition bias
Median phase one scores for the eight outcomes included in the 
COS, or their nearest approximations, were compared between 
participants who completed all three phases of the Delphi process 
and those who completed phase one only. No statistically signifi-
cant differences were seen between any of these groups (table 6).
DIsCussIOn
Using robust consensus methodology, we have enabled key stake-
holders to identify eight outcomes as being the most important 
in determining the overall success of treatment of a child born 
with gastroschisis. These are: death, sepsis, growth, number of 
operations, severe gastrointestinal complication, time on paren-
teral nutrition, liver disease and quality of life for the child. By 
developing the COS using Delphi methodology combined with 
detailed discussion of outcomes at a consensus meeting, we 
anticipate that the included outcomes are relevant to clinical 
practice, parents and patients and appropriate for differentiating 
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Table 5 Proposed time-points for measurement of core outcomes
Cohort studies Intervention studies
28 days of age 30-day postintervention
90-day postintervention
One year of age One-year postintervention
Five years of age Five-year postintervention
Ten years of age Ten-year postintervention
Every subsequent 10 years Every subsequent 10 years
Table 6 Comparison of median phase one scores for outcomes 
included in the core outcome set between participants in each panel 
who completed all three phases of the Delphi process and those who 
only completed phase one
Outcome Panel
P value from Wilcoxon 
rank-sum test
Death Neonatal 0.3
Non-neonatal 1
Personal experience 0.9
Sepsis Neonatal 0.4
Non-neonatal 0.7
Personal experience 0.7
Growth Neonatal 0.4
Non-neonatal 0.6
Personal experience 0.2
Number of operations Neonatal 0.9
Non-neonatal 1
Personal experience 0.2
Severe gastrointestinal 
complication
Neonatal 0.6
Non-neonatal 0.6
Personal experience 0.5
Time on parenteral 
nutrition
Neonatal 0.8
Non-neonatal 0.7
Personal experience 0.6
Liver disease Neonatal 0.5
Non-neonatal 0.9
Personal experience 0.1
Quality of life Neonatal 0.8
Non-neonatal 0.4
Personal experience 0.4
the relative merits of gastroschisis treatments. Furthermore, the 
COS has been designed to be practical to use in multiple study 
designs. The number of outcomes is relatively small and each has 
been robustly defined, with an appropriate measure and time-
point for reporting identified. This level of detail should enable 
the immediate practical implementation of the COS.
A particular strength of this process has been the involvement 
of a wide range of stakeholder groups including parents of chil-
dren born with gastroschisis. Unfortunately, however, there were 
no individuals born with gastroschisis who completed all three 
phases of the study. The difficulty engaging adults treated for 
gastroschisis as a child may be due to the fact that many have no 
ongoing active involvement with medical services or charities. 
It is difficult to know if this population of adults do not have 
regular contact with medical services because they are symptom 
free or because they have become detached from these services. 
If the former is true, the COS will likely remain fully represen-
tative of the outcomes that are important in determining treat-
ment success, as the majority of ‘experience’ of gastroschisis 
will be from the parental point of view. However, if it is the 
latter, and there are differences in opinion of which outcomes 
are important between parents, and adults who were treated for 
gastroschisis as a child, then the COS may under-represent the 
treated adult’s opinion.
In addition to the difficulties that were experienced recruiting 
people born with gastroschisis to the personal experience panel, 
the attrition rate in this panel was also higher than in the two 
other panels. However, this was still in line with other published 
studies.11 It is unclear why the attrition rate was higher, but we 
would speculate that the demographics of those who are likely to 
be members of the personal experience panel might have influ-
enced their ability to find time to complete all three phases of the 
study. There were, however, no differences identified in scoring 
patterns between those participants who completed all three 
phases of the Delphi process and those who only completed 
phase one, and we therefore do not believe that the identified 
attrition will have affected the results of the process.
Currently, many COS development processes conduct inter-
views with non-medical participants prior to starting the Delphi 
process. These interviews are used to identify outcomes that 
are important to patients but not reported by the existing 
literature. In this COS development process, we opted not to 
conduct interviews and instead gave participants the opportunity 
to propose new outcomes in phase one of the Delphi process. 
This decision was based on our experience of developing a 
Hirschsprung’s disease COS,10 where analysis of the additional 
outcomes proposed by participants, and comments left during 
the Delphi process reassured us that the likelihood of missing 
important outcomes by not conducting qualitative interviews 
prior to starting the Delphi process was low. In addition, we 
believed there to be significant benefit to not conducting qual-
itative interviews in that it reduced the cost and time necessary 
to develop the COS and therefore increased the efficiency with 
which its use could be implemented in future research. Interest-
ingly, despite some methodological differences, there is overlap 
between the outcomes included in this COS, outcomes included 
in the recently developed Hirschsprung’s disease COS10 and 
a paediatric asthma COS.12 All three have included death and 
quality of life, as well as a measure of the need for repeated 
medical intervention. Commonality between these COSs may 
suggest a role for developing a paediatric COS that is appli-
cable to all conditions with significant childhood morbidity and 
that can then be augmented with smaller disease-specific COSs. 
Results of two further paediatric surgical COSs that are currently 
in development for appendicitis13 and burns14 will help to inform 
this discussion, as will the results of the Core outcomes in neona-
tology (COIN) study,15 which is developing a neonatal COS.
While some of the outcomes included in the COS such as 
time on parenteral nutrition and number of operations were 
already frequently investigated in gastroschisis studies, there 
was significant variation in the way they were defined, or the 
time-point at which they were measured.7 This has meant that 
although researchers were investigating outcomes of importance 
to patients, the fact that they were doing so in different ways 
was impeding the development of a meaningful evidence base.4 
Developing this COS has allowed key stakeholders to achieve 
consensus on definitions and measures that should be used for 
each of these already commonly investigated core outcomes. 
Promoting the use of these definitions will improve the quality 
of the evidence base supporting the management of infants with 
gastroschisis, without significantly altering the outcomes that 
researchers are investigating. Other core outcomes including 
growth and quality of life were very infrequently investigated in 
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gastroschisis studies.7 It is likely that these have not previously 
been frequently investigated, because it is difficult and expensive 
to collect data in relation to them. Identifying these outcomes as 
important to key stakeholders therefore has significant implica-
tions for researchers, journal editors and funders, as it will alter 
the way in which studies are designed, funded and reviewed for 
publication.
While the COS has identified eight outcomes that, because of 
their importance to key stakeholders, should be investigated in 
all studies comparing treatments for children born with gastro-
schisis, there are still further steps that must be taken before the 
patient benefit of this work is realised. Using the COS in clinical 
practice, audit, observational studies and randomised controlled 
trials will start to establish data in the public domain that can 
be meta-analysed to meaningfully inform the ongoing debate 
around the ideal management of children born with gastro-
schisis. If this COS facilitates the generation of high-quality 
evidence to support optimal management strategy, then patient 
care can be standardised, and outcomes will begin to improve.
Acknowledgements The Next stage in Evidence based paediatric surgery 
Treatment Strategies (NETS) programme of work is designed to develop and 
implement the use of core outcome sets in paediatric surgery. As part of this 
programme of work, the NETS1G collaboration was formed to develop a gastroschisis 
core outcome set. In addition, we would like to thank the following people who 
through completion of all three phases of the Delphi process contributed significantly 
to the development of this gastroschisis core outcome set: Cassie Aldridge, Janet 
Berrington, Gemma Bond, Sarah Bradley, Joanna Brown, Pamela Cairns, Marcela 
Campbell, Dionicia Caudill, Danielle Childs, Terrill Coleman, Eleri Cusick, Mark 
Davenport, Sarah Davidson, ChrisDriver, Mallisa Gaydon, Diane Gerrard, Jonathan 
Goring, Neelam Gupta, Jason Hall, Philip Hammond, Jacky Henderson, Rebecca 
Holmes, Robert Ironton, Bruce Jaffray, Mark Johnson, Rhiannon Jones, Gina Koss, 
Amber Lavene, Benjamin Lewis, Karen Marchant, Luise Marino, Ashish Minocha, 
Milly Moore, Cate Nicholl, Freya Pearson, Isaac Philip, Victoria Phillips, Alex Philpott, 
Kerrie Piper, Kaitlyn Pitman, Victoria Puddy, Clare Rees, Alison Sharard, Julia Shirtliffe, 
Jen Sobczak, Charlotte Spraggs, Cindy Sykes, Silke Wagener, Theodoric Wong and 
Amanda Young.
Collaborators The following people form the NETS1G collaboration: Ceri Caven, 
relative of a child born with gastroschisis; Lily Chapman, Relative of a child born 
with gastroschisis; Brian Davies, Nottingham Children’s Hospital; Melanie Drewett, 
Southampton Children’s Hospital; Simon Eaton, Institute for Child Health, Great 
Ormond Street Hospital; Sijo Francis, St Georges Hospital; Oliver Gee, Birmingham 
Children’s Hospital; Anne Hickey, King’s College Hospital; Jonathan Hind, King’s 
College Hospital; Anna-May Long, National Perinatal Epidemiology Unit; Heather 
Norris, Bristol Children’s Hospital; Gareth Penman, Sheffield Children’s Hospital; 
Bernadette Reda, Birmingham Children’s Hospital; Davee Ridgers, relative of a child 
born with gastroschisis; Claire Ridgers, relative of a child born with gastroschisis; 
Clare Skerritt, Evelina Children’s Hospital; Martin Ward-Platt, Royal Victoria Infirmary; 
Naomi Wright, King’s College Hospital.
Contributors BSRA was responsible for the design of the study, day-to-day 
management of the study, analysis of data and drafting of the manuscript. NJH, 
ARR, SSM, JJK and MK were responsible for design of the study, management of the 
study and contributed to critical revisions of the manuscript. Members of NETS1G 
collaboration contributed critically to the academic content of the study and have 
reviewed and critically revised the manuscript.
Funding MK is funded by a National Institute for Health Research (NIHR) 
Professorship. BSRA is funded by an NIHR Doctoral Research Fellowship. NJH is 
supported by the NIHR through the NIHR Southampton Biomedical Research Centre 
in nutrition. 
Disclaimer The views expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the Department of Health. The NIHR had no role 
in the design and conduct of the study; the collection, management, analysis and 
interpretation of the data; the preparation, review and approval of the manuscript; or 
the decision to submit the manuscript for publication.
Competing interests None declared.
ethics approval The Health Research Authority deemed the study to be service 
evaluation/service development, and review by an ethics committee was therefore 
not required (http://www. hra- decisiontools. org. uk/ research/). 
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
RefeRences
 1 Owen A, Marven S, Johnson P, et al. Gastroschisis: a national cohort study to describe 
contemporary surgical strategies and outcomes. J Pediatr Surg 2010;45:1808–16.
 2 Kilby MD. The incidence of gastroschisis Is increasing in the UK, particularly among 
babies of young mothers. BMJ 2006;332:250–1.
 3 Allin BS, Tse WH, Marven S, et al. Challenges of improving the evidence base in 
smaller surgical specialties, as highlighted by a systematic review of gastroschisis 
management. PLoS One 2015;10:e0116908.
 4 Kunz SN, Tieder JS, Whitlock K, et al. Primary fascial closure versus staged closure with 
silo in patients with gastroschisis: a meta-analysis. J Pediatr Surg 2013;48:845–57.
 5 Williamson P, Altman D, Blazeby J, et al. Driving up the quality and relevance 
of research through the use of agreed core outcomes. J Health Serv Res Policy 
2012;17:1–2.
 6 Allin B, Ross A, Marven S, et al. Development of a core outcome set for use in 
determining the overall success of gastroschisis treatment. Trials 2016;17:360.
 7 Allin BS, Irvine A, Patni N, et al. Variability of outcome reporting in Hirschsprung’s 
Disease and gastroschisis: a systematic review. Sci Rep 2016;6:38969.
 8 Ross AR, Hall NJ. Outcome reporting in randomized controlled trials and 
systematic reviews of gastroschisis treatment: a systematic review. J Pediatr Surg 
2016;51:1385–9.
 9 Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook: version 1.0. Trials 
2017;18(Suppl 3):280.
 10 Allin BSR, Bradnock T, Kenny S, et al. NETS1HD study: development of a 
Hirschsprung’s disease core outcome set. Arch Dis Child 2017;102:1143–51.
 11 McNair AG, Whistance RN, Forsythe RO, et al. Core outcomes for colorectal cancer 
surgery: a consensus study. PLoS Med 2016;13:e1002071.
 12 Sinha IP, Gallagher R, Williamson PR, et al. Development of a core outcome set for 
clinical trials in childhood asthma: a survey of clinicians, parents, and young people. 
Trials 2012;13:103.
 13 Sherratt FC, Eaton S, Walker E, et al. Development of a core outcome set to determine 
the overall treatment success of acute uncomplicated appendicitis in children: a study 
protocol. BMJ Paediatr Open 2017;1:e000151.
 14 Young A, Brookes S, Rumsey N, et al. Agreement on what to measure in randomised 
controlled trials in burn care: study protocol for the development of a core outcome 
set. BMJ Open 2017;7:e017267.
 15 Webbe J, Brunton G, Ali S, et al. Developing, implementing and disseminating a core 
outcome set for neonatal medicine. BMJ Paediatr Open 2017;1:e000048.
copyright.
 o
n
 4 February 2019 by guest. Protected by
http://fn.bmj.com/
Arch D
is Child Fetal Neonatal Ed: first published as 10.1136/archdischild-2017-314560 on 14 M
arch 2018. Downloaded from
 
